Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2019, Article ID 1932036, 7 pages
https://doi.org/10.1155/2019/1932036
Clinical Study

PPARG2 Pro12Ala and TNFα -308G>A Polymorphisms Are Not Associated with Heart Failure Development in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting

1Institute of Cardiology, Intensive Cardiac Therapy Clinic, Alpejska St., 04-628 Warsaw, Poland
2Medical University of Bialystok, Department of General and Experimental Pathology, Mickiewicza 2c, 15-222 Bialystok, Poland
3Institute of Oncology, Department of Molecular and Translational Oncology, Wawelska 15B St., 02-034 Warsaw, Poland

Correspondence should be addressed to Izabela Wojtkowska; lp.po@tjowalebazi

Received 31 December 2018; Revised 31 March 2019; Accepted 11 April 2019; Published 2 June 2019

Academic Editor: Swasti Tiwari

Copyright © 2019 Izabela Wojtkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Stumvoll and H. Häring, “The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism,” Diabetes, vol. 51, no. 8, pp. 2341–2347, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. XL. Wang, J. Oosterhof, and N. Duarte, “Peroxisome proliferator-activated receptor gamma C161→T polymorphism and coronary artery disease,” in Cardiovascular Research, vol. 44, pp. 588–594, 1999. View at Google Scholar
  4. J. Skogsberg, A. D. McMahon, F. Karpe, A. Hamsten, C. J. Packard, and E. Ehrenborg, “Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men,” Journal of Internal Medicine, vol. 254, no. 6, pp. 597–604, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Flavell, Y. Jamshidi, E. Hawe et al., “Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease,” Circulation, vol. 105, no. 12, pp. 1440–1445, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Blüher, T. Klemm, T. Gerike, H. Krankenberg, G. Schuler, and R. Paschke, “Lack of association between peroxisome proliferator-activated receptor-gamma-2 gene variants and the occurrence of coronary heart disease in patients with diabetes mellitus,” European Journal of Endocrinology, vol. 146, no. 4, pp. 545–551, 2002. View at Google Scholar · View at Scopus
  7. U. Vogel, S. Segel, C. Dethlefsen et al., “PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes,” BMC Medical Genetics, vol. 10, no. 52, 2009. View at Publisher · View at Google Scholar
  8. L. P. Wang, L. R. Zhao, H. W. Cui, M. R. Yan, L. Yang, and X. L. Su, “Association between PPARgamma2 Pro12Ala polymorphism and myocardial infarction and obesity in Han Chinese in Hohhot, China,” Genetics and Molecular Research, vol. 11, no. 3, pp. 2929–2938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Xu, J. Xu, B. Sun et al., “The effect of PPARG gene polymorphisms on the risk of coronary heart disease: a meta-analysis,” Molecular Biology Reports, vol. 40, no. 2, pp. 875–884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. Wu, Y. Lou, W. Jin et al., “The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma-2 gene (PPARgamma2) is associated with increased risk of coronary artery disease: a meta-analysis,” PLoS ONE, vol. 7, no. 12, Article ID e53105, 2012. View at Publisher · View at Google Scholar
  11. Z. Wu, Y. Lou, W. Jin, Y. Liu, L. Lu, and G. Lu, “The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARgamma) is associated with risk of coronary artery disease: a meta-analysis,” Molecular Biology Reports, vol. 40, no. 4, pp. 3101–3112, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Zhang, X. Yang, F. Bian et al., “TNF-alpha promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-kappaB and PPAR-gamma,” Journal of Molecular and Cellular Cardiology, vol. 72, pp. 85–94, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. Q. Yao, L. Nordfors, J. Axelsson et al., “Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy,” Atherosclerosis, vol. 182, pp. 105–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Kursawe, V. D. Dixit, P. E. Scherer et al., “A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents,” Diabetes, vol. 65, no. 3, pp. 610–618, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky, “Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro,” The American Journal of Pathology, vol. 153, no. 1, pp. 17–23, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Wojtkowska, A. Tysarowski, K. Seliga et al., “PPAR gamma expression levels during development of heart failure in patients with coronary artery disease after coronary artery bypass-grafting,” PPAR Research, vol. 2014, Article ID 242790, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Wojtkowska, T. A. Bonda, J. Wolszakiewicz et al., “Myocardial expression of ppargamma and exercise capacity in patients after coronary artery bypass surgery,” PPAR Research, vol. 2017, Article ID 1924907, 7 pages, 2017. View at Google Scholar · View at Scopus
  18. J.-P. Mira, A. Cariou, F. Grall et al., “Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study,” Journal of the American Medical Association, vol. 282, no. 6, pp. 561–568, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Nejati, S. Naeimipour, A. Salehi, and M. Shahbazi, “Association of tumor necrosis factor-alpha gene promoter polymorphism and its mRNA expression level in coronary artery disease,” Meta Gene, vol. 18, pp. 122–126, 2018. View at Publisher · View at Google Scholar · View at Scopus
  20. A. H. Hajeer and I. V. Hutchinson, “nfluence of TNFalpha gene polymorphisms on TNFalpha production and disease,” Human Immunology, vol. 62, no. 11, pp. 1191–1199, 2001. View at Publisher · View at Google Scholar
  21. M. Galiñanes, M. James, V. Codd, A. Baxi, and L. Hadjinikolaou, “TNF-alpha gene promoter polymorphism at nucleotide -308 and the inflammatory response and oxidative stress induced by cardiac surgery: role of heart failure and medical treatment,” European Journal of Cardio-Thoracic Surgery, vol. 34, no. 2, pp. 332–337, 2008. View at Publisher · View at Google Scholar
  22. S. C. Sookoian, C. González, and C. J. Pirola, “Meta-analysis on the G-308A tumor necrosis factor alpha gene variant and phenotypes associated with the metabolic syndrome,” Obesity Research, vol. 13, no. 12, pp. 2122–2131, 2005. View at Publisher · View at Google Scholar
  23. H. Lakka, T. A. Lakka, T. Rankinen et al., “The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study,” Vascular Pharmacology, vol. 44, no. 5, pp. 377–383, 2006. View at Publisher · View at Google Scholar
  24. P. Zhang, X. Wu, G. Li et al., “Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease: a systematic review and meta-analysis,” Medicine, vol. 96, no. 14, Article ID e6569, 2017. View at Publisher · View at Google Scholar
  25. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance,” The Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Marfella, K. Esposito, M. Siniscalchi et al., “Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women,” Diabetes Care, vol. 27, no. 1, pp. 47–52, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Maciejewska-Karlowska, M. Sawczuk, P. Cieszczyk, A. Zarebska, and S. Sawczyn, “Association between the Pro12Ala polymorphism of the peroxisome proliferator- activated receptor gamma gene and strength athlete status,” PLoS ONE, vol. 8, no. 6, Article ID e67172, 2013. View at Publisher · View at Google Scholar · View at Scopus